Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The 336 merged reexam decision

Yes, they know what prior art is mentioned, but have not idea whether any of it will be the cause for a rejection. Why assume the need for an ammendment if none is needed? Wouldn't the patent owner be indicating where he thought a weakness was by acting first? Appreciate your thoughts. Thanks Opty

Share
New Message
Please login to post a reply